Spyre Therapeutics, Inc.

Developing long-acting antibodies and combinations targeting validated mechanisms in inflammatory bowel disease.

Back to company catalog

Immunology / IBD · Extended half-life monoclonal antibodies · Clinical (Phase 2)

Compare report options